Key Insights

Highlights

Success Rate

100% trial completion (above average)

Treatment Research

7 treatments under study, led by Venetoclax

Research Leaders

11 sponsors active, led by Vertex Pharmaceuticals Incorporated

Related Conditions

Often studied with 4 related conditions

Clinical Risk Assessment

Based on trial outcomes

Low Risk

Score: 27/100

Termination Rate

0.0%

0 terminated out of 4 trials

Success Rate

100.0%

+13.4% vs benchmark

Late-Stage Pipeline

25%

1 trials in Phase 3/4

Results Transparency

50%

1 of 2 completed with results

Key Signals

1 with results100% success

Data Visualizations

Phase Distribution

3Total
Not Applicable (1)
Phase 2 (1)
Phase 3 (1)

Trial Status

Recruiting2
Completed2

Trial Success Rate

100.0%

Benchmark: 86.6%

Based on 2 completed trials

Clinical Trials (4)

Showing 4 of 4 trials
NCT05099471Phase 2Recruiting

Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia

NCT07126678Not ApplicableRecruiting

Fixed-Duration Zanubrutinib, Bendamustine, and Obinutuzumab (ZBG) in Treatment-Naïve Advanced Stage Follicular Lymphoma

NCT00852618Completed

Intensive Viral Dynamics Substudy of A5248

NCT01241760Phase 3Completed

VX-950-C211 - A Dosing Regimen Study (Twice Daily Versus Every 8 Hours) of Telaprevir in Treatment-naïve Participants With Genotype 1 Chronic Hepatitis C Virus Infection

Showing all 4 trials

Research Network

Common Treatments

  • Venetoclax1
  • Telaprevir1
  • Venetoclax Rituximab1
  • Zanubrutinib Bendamustine And Obinutuzumab1
  • Peginterferon Alfa2a1

Active Sponsors

  • Vertex Pharmaceuticals Incorporated1
  • National Institute of Allergy and Infectious Diseases (NIAID)1
  • Pfizer1
  • University Hospital Schleswig-Holstein1
  • Janssen Infectious Diseases BVBA1

Top Investigators

Related Conditions

  • Hiv Infections1
  • Waldenstrom Macroglobulinemia1
  • Genotype 1 Chronic Hepatitis C1
  • Follicular Lymphoma1

Activity Timeline